ChemicalBook Product Catalog Biochemical Engineering Amino Acids and Derivatives Leucine derivatives N-Acetyl-L-leucine

N-Acetyl-L-leucine

Product NameN-Acetyl-L-leucine
CAS1188-21-2
MFC8H15NO3
MW173.21
EINECS214-706-3
MOL File1188-21-2.mol

Chemical Properties

Melting point	187-190 °C(lit.)
alpha	-24.5 º (c=4, MeOH)
Boiling point	303.86°C (rough estimate)
Density	1.1599 (rough estimate)
refractive index	-22 ° (C=5, EtOH)
storage temp.	Sealed in dry,Room Temperature
solubility	DMSO (Slightly), Ethanol (Slightly), Water (Slightly, Heated)
pka	3.67±0.10(Predicted)
form	Crystalline Powder
color	White
optical activity	[α]25/D 23±3°, c = 2 in ethanol
Water Solubility	0.81 g/100 mL (20 ºC)
BRN	1724849
Major Application	peptide synthesis
InChI	1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1
InChIKey	WXNXCEHXYPACJF-ZETCQYMHSA-N
SMILES	CC(C)C[C@H](NC(C)=O)C(O)=O
CAS DataBase Reference	1188-21-2(CAS DataBase Reference)
NIST Chemistry Reference	L-leucine, n-acetyl-(1188-21-2)
EPA Substance Registry System	L-Leucine, N-acetyl- (1188-21-2)

Safety Information

Hazard Codes	Xi
Risk Statements	36/37/38
Safety Statements	24/25-36-26
WGK Germany	3
TSCA	TSCA listed
HazardClass	IRRITANT
HS Code	29241900
Storage Class	11 - Combustible Solids

MSDS

Provider	Language
ACROS	English
SigmaAldrich	English
ALFA	English

Usage And Synthesis

Chemical Properties

White crystalline powder

Uses

N-Acetyl-L-(-)-leucine is used in the preparation of small molecule inhibitors of anti-apoptotic Bcl-2 family proteins. Also used in the preparation of amphiphilic copolymers involving hydrophobic amino acid and oligopeptide side chains for optical tumor imaging in vivo.

Definition

ChEBI: The N-acetyl derivative of L-leucine.

reaction suitability

reaction type: C-H Activation
reaction type: solution phase peptide synthesis
reagent type: catalyst
reaction type: Peptide Synthesis

Pharmaceutical Applications

N-acetyl-l-leucine (NALL) has shown therapeutic potential for neurodegenerative diseases, including in prodromal stages of Parkinson's disease (PD). Researches show that the therapeutic potential of NALL for PD by its protective effects on α-synuclein pathology and synaptic function in vulnerable dopaminergic neurons^[1].

in vivo

Levacetylleucine (60 mg/kg, i.v., administration on days 1, 2 and 3 for 15 days) decreases the postural imbalance scores and accelerates the course of postural compensation induced by UL in rats^[3].
Levacetylleucine (100 mg/kg, oral gavage, administration daily for 28 days) attenuates cortical cell death afer traumatic brain injury (TBI) in N-Acetyl-L-leucine-treated TBI mouse cortices^[4].

Animal Model:	Male Sprague-Dawley rats (mean 400±20 g, age 3 months) after chemical UL^[3]
Dosage:	60 mg/kg
Administration:	i.v., 15 days
Result:	Significantly decreased the postural imbalance scores on 7 day and accelerated the course of postural compensation by about 6 days in rats.

Animal Model:	C57/BL6 mice^[4]
Dosage:	100 mg/kg
Administration:	oral gavage, administration daily for 1-28 days
Result:	Did not afect food intake and body weight in mice.

Animal Model:	N-Acetyl-L-leucine-treated TBI mouse cortices^[4]
Dosage:	100 mg/kg
Administration:	oral gavage, administration daily for 28 days
Result:	Prevented cortical cell death which peaks at early time points (day 1) afer TBI in N-Acetyl-L-leucine-treated TBI mouse cortices.

IC 50

Human Endogenous Metabolite

References

[1] Song, P., Chen, C., Franchini, R., Duong, B., Wang, Y.-Z., Coukos, R., Xie, Z., Savas, J. N., Zhou, Y., Bertoldi, M., Surmeier, D. J., Parisiadou, L., & Krainc, D. (2026). N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in Parkinson's disease models. Journal of Clinical Investigation, 136 5. https://doi.org/10.1172/JCI196137

N-Acetyl-L-leucine

Chemical Properties

Safety Information

MSDS

Usage And Synthesis

Preparation Products And Raw materials

N-Acetyl-L-leucine Supplier

N-Acetyl-L-leucine manufacturers

Related articles

Related Product Information